Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

about

Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q52770382

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@en

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@nl

type

Item

label

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@en

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@nl

prefLabel

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@en

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@nl

P1476

Use of minimal residual diseas ...... chronic lymphocytic leukemia.

@en

P2093

Anna Christofides

http://www.w3.org/2001/XMLSchema#string

Carol Ward

http://www.w3.org/2001/XMLSchema#string

Carolyn Owen

http://www.w3.org/2001/XMLSchema#string

David MacDonald

http://www.w3.org/2001/XMLSchema#string

Nathalie Johnson

http://www.w3.org/2001/XMLSchema#string

Tatiana Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Next-generation sequencing: advances and applications in cancer diagnosis

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

P304

2777-2785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1318439

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28509580

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

lymphocyte